SCHEMBL755855

SCHEMBL755855

CC(=O)C(=O)OC1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.48
NAAA Q02083 2/20 0.44
HTT P42858 2/20 0.43
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CYP2C19 P33261 1/20 0.41
CYP19A1 P11511 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
GPR35 Q9HC97 1/20 0.36
MMP1 P03956 1/20 0.36
MMP9 P14780 1/20 0.36
MMP12 P39900 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
FABP7 O15540 1/20 0.35
FABP5 Q01469 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013625 0.98 EPHX1 (0.45) EPHX1NAAAHTTCA12CA1
SCHEMBL4672536 0.88 EPHX1 (0.50) EPHX1NAAAHTTCA12CA1
SCHEMBL4676851 0.85 EPHX1 (0.47) EPHX1NAAAHTTCA12CA1
SCHEMBL2999385 0.85 EPHX1 (0.54) EPHX1NAAAHTTCA12CA1
SCHEMBL25410637 0.82 EPHX1 (0.46) EPHX1NAAAHTTCA12CA1
SCHEMBL10602595 0.82 EPHX1 (0.46) EPHX1NAAAHTTCA12CA1
SCHEMBL887989 0.82 EPHX1 (0.46) EPHX1NAAAHTTCA12CA1
SCHEMBL22480 0.82 EPHX1 (0.46) EPHX1NAAAHTTCA12CA1
SCHEMBL17159433 0.82 EPHX1 (0.46) EPHX1NAAAHTTCA12CA1
SCHEMBL18822970 0.82 EPHX1 (0.46) EPHX1NAAAHTTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550277-B2 D-amino acid dehydrogenase and method of making D-amino acids CODEXIS, INC. (US) 2009-06-23 US claimed
US-20080182972-A1 D-amino acid dehydrogenase and method of making D-amino acids INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2008-07-31 US claimed
EP-1896574-A2 D-AMINO ACID DEHYDROGENASE AND METHOD OF MAKING D-AMINO ACIDS BioCatalytics Inc. (US) 2008-03-12 EP claimed
WO-2006113085-A2 D-AMINO ACID DEHYDROGENASE AND METHOD OF MAKING D-AMINO ACIDS BIOCATALYTICS, INC. (US) 2006-10-26 WO claimed
US-20260076935-A1 PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2026-03-19 US disclosed
EP-4683625-A2 PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE The Trustees Of Columbia University In The City Of New York (US) 2026-01-28 EP disclosed
WO-2025058667-A2 PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-03-20 WO disclosed
EP-4329743-A1 PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES Birkenmeier, Gerd (DE) 2024-03-06 EP disclosed
CN-116462589-A Treatment method of byproduct tar in cyclohexyl methacrylate production 万华化学集团股份有限公司 2023-07-21 CN disclosed
CN-116462589-A Treatment method of byproduct tar in cyclohexyl methacrylate production 万华化学集团股份有限公司 2023-07-21 CN disclosed
WO-2022228651-A1 PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES BIRKENMEIER GERD (DE) 2022-11-03 WO disclosed
WO-2022228652-A1 MEANS AND METHOD FOR TREATING VIRAL INFECTIONS BIRKENMEIER GERD (DE) 2022-11-03 WO disclosed
WO-2006108681-A2 SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) 2006-10-19 WO disclosed
CN-1191254-C Fused pyrrole compounds, pharmaceutical composition containing the same, and the use thereof MARCKLE GMBH (DE) 2005-03-02 CN disclosed
CN-1418217-A Fused pyrrole compounds, pharmaceutical composition containing the same, and the use thereof MARCKLE GMBH (DE) 2003-05-14 CN disclosed
US-5290325-A Compounds such as methyl pyruvate to lower air pollution UNION OIL COMPANY OF CALIFORNIA (US) 1994-03-01 US disclosed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 US disclosed
US-4472380-A CARBOXYALKYL DIPEPTIDE DERIVATIVES MERCK & CO., INC. (US) 1984-09-18 US disclosed
US-4374829-A Aminoacid derivatives as antihypertensives MERCK & CO., INC. (US) 1983-02-22 US disclosed
EP-0012401-A1 Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them MERCK & CO. INC. (US) 1980-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260076935-A1 PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE PC, PDK1, PDK4 EPHX1 151/4885NAAA 4242/4885HTT 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.